Within the past several years, immune checkpoint inhibitors (ICIs) have become more widespread in the treatment of malignancies. In that report, the patient was diagnosed with bilateral uveitis with pupillary adhesions at the start of treatment with pembrolizumab.[12] He later developed three relapses of bilateral anterior uveitis following two, six, and eight months of treatment. In the future, polymorphisms in CTLA-4 and PD-1 genes, which have been associated with multiple autoimmune diseases,[16],[17] may allow for improved risk assessment and monitoring for patients receiving ICI therapy. [Extracted from the article]